Skip to main content
Journal of Open Innovation: Technology, Market, and Complexity

Table 16 Distribution of the development phase in the cardiovascular dataset

From: Valuations using royalty data in the life sciences area—focused on anticancer and cardiovascular therapies

Development

No. of hit

%

in vitro activity

3

9.68

Preclinical

3

9.68

Phase I

4

12.90

Phase II

2

6.45

Phase III

7

22.58

NDA/BLA

12

38.71

Total deal number

31

100.00

Back to article page